The US pharmaceutical drug delivery market is projected to rise from USD 0.94 billion in 2026 to USD 1.24 billion by 2031 at a 5.8% CAGR. Injectables, oncology applications, and home care settings are expected to post the fastest growth.
Origin Genomics launches to pursue germline gene editing research despite US prohibitions, while Thermo Fisher completes its $8.88 billion acquisition of Clario Holdings. Lucid Diagnostics reports Q4 revenue growth, and multiple partnerships form across the diagnostics and synthetic biology sectors.
The pharmaceutical industry is experiencing recovery driven by innovation in drug development, aggressive M&A activity, and expansion of drug development services. The sector faces both opportunities and headwinds including pipeline setbacks and regulatory pressures.
Three new market reports project significant expansion in pharmaceutical R&D outsourcing, the U.S. pharmaceutical market, and biotechnology services outsourcing, driven by innovation, aging populations, and cost efficiency needs through 2035.
The global epigenetics drugs and diagnostic technologies market is projected to reach USD 79.03 billion by 2035, while the genomics in cancer care market is expected to hit USD 108.69 billion, driven by precision medicine advances and AI integration.
